Abstract:Abstract Introduction Atopic dermatitis (AD) is a chronic, relapsing, inflammatory, pruritic skin disease. More than 50% of cases begin during the first year of life and at least 80% of affected children have onset before the age of 5. A bimodal distribution is seen, with the condition improving in late childhood and only a minority of cases persisting in adolescence and adulthood. The widespread and persistent dermatitis and severe pruritus have a substantial impact on sleep and quality of life for both affected children and their parents. Childhood depression and anxiety can lead to negative parenting behaviours, affecting both children and parental well-being. In some cases, the dermatitis is complicated by secondary bacterial or viral infections. New generation biologics and JAK inhibitors have emerged as a promising treatment option for moderate to severe cases of atopic dermatitis and transformed the face of dermatology. Objectives This abstract presents a review of our experience in prescribing dupilumab and upadacitinib, in the management of AD among paediatric patients. In this case series, we share our experience of using these new medications in managing paediatric atopic dermatitis. The majority of these patients had failed treatment with topical steroids, calcineurin inhibitors, and systemic immunosuppressants, or they have contraindications for prescribing immunosuppressors currently used as first step systemic treatment, e.g. patients with inflammatory bowel disease or liver transplant patients. Methods Over the last 18 months, we treated a total of 9 paediatric patients (7 Dupilumab and 2 Upadacitinib) with moderate to severe AD using these medications. This retrospective study encompasses a cohort of paediatric patients diagnosed with moderate to severe AD, who received treatment with dupilumab or upadacitinib within the specified timeframe at our institution. Each patient's medical records were reviewed to gather demographic information, disease characteristics, treatment regimens, adverse events, and treatment responses. Results Following initiation of treatment with dupilumab or upadacitinib, significant improvements in disease severity were observed across the patient cohort. Objective assessments utilising standardised clinical scoring tools revealed marked reductions in disease activity scores post-treatment, including the Eczema Area and Severity Index (EASI), Dermatology quality of life questionnaire (DLQI) and the Investigator’s GlobaL Assessment (IGA). Our findings suggest that biologics significantly improved the symptoms and quality of life in our paediatric severe eczema patients. Most patients experienced a rapid reduction in pruritus, erythema, and excoriation within a few weeks of starting biologic therapy. Additionally, we observed a decrease in the frequency of flares and the need for oral corticosteroids in our patients. Most of the patients on Dupilumab were prescribed prophylactic Hypromellose drops and VitaPOS eye ointment. Notably, Dupilumab associated conjunctivitis was not reported in any of the cases. Conclusion Overall, our case series suggests that biologic agents are effective and well-tolerated in the management of moderate to severe AD in the paediatric population. In our experience, we have seen a reduction in pruritus, improvement in sleep quality, and overall better control of the disease with the use of dupilumab and upadacitinib in paediatric patients. These novel medications not only provide relief from the symptoms of atopic dermatitis but so far, offer a safe and effective long-term treatment option for children who have failed to respond to conventional therapies. Our case series contributes valuable insights into the real-world utilisation of biologic agents, specifically dupilumab and upadacitinib, in the management of severe AD.

Secukinumab therapy for paediatric patients with various phenotypes of congenital ichthyosis

Transcriptomic response of peripheral blood mononuclear cells to secukinumab in epidermolytic ichthyosis

Vitamin D Supplementation in Congenital Ichthyosis: A Case Series

PA02 A case series of refractory, paediatric atopic dermatitis effectively treated with dupilumab in combination with abrocitinib

Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses - a retrospective analysis

Real-world Data on the Clinical Use of Secukinumab in Pediatric Generalized Pustular Psoriasis: A 48-Week Retrospective Study

Clinical efficacy and safety of secukinumab in the treatment of generalized pustular psoriasis in the pediatric population: a systematic review of the literature

A Case Series of Refractory Pediatric Atopic Dermatitis Effectively Treated With Dupilumab in Combination With Abrocitinib

Treatment of Netherton Syndrome in Pediatrics with Upadacitinib

Successful treatment with secukinumab of psoriasis‐like dermatitis in a patient with holocarboxylase synthetase deficiency

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials

Successful Treatment of Severe Pityriasis Rubra Pilaris with Secukinumab in a 3-Year-old Boy

727 - Case series on real-world experience of biologics in the management of atopic dermatitis in paediatric population at King’s College Hospital, London

Rare Types of Congenital Ichthyoses

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

AB1123 EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIASIS

Real‐world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis

Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: lessons from treatment in adults and the way forward

An excellent response to topical therapy of four congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome patients with an increased concentration of simvastatin ointment

Congenital ichthyosis: a multidisciplinary approach in a neonatal care unit